Elsevier

Thrombosis Research

Volume 195, November 2020, Pages 128-135
Thrombosis Research

Full Length Article
Safety and efficacy of drug eluting stents vs bare metal stents in patients with atrial fibrillation: A systematic review and meta-analysis

https://doi.org/10.1016/j.thromres.2020.07.010Get rights and content

Highlights

  • In patients with AF undergoing PCI, DES showed similar rate of major bleeding and MACE than BMS.

  • DES showed a trend of a lower risk of TVR and a similar risk of stent thrombosis in comparison to BMS.

  • DAT seems to be a safer antithrombotic therapy compared with TAT.

Abstract

Objective

A systematic review and meta-analysis was performed to evaluate the safety and efficacy of drug-eluting stents (DES) vs bare-metal stents (BMS) in atrial fibrillation (AF) patients.

Methods

We systematically searched 5 engines until May 2019 for cohort studies and randomized controlled trials (RCTs). Primary outcomes were major bleeding and major adverse cardiac events (MACE) including cardiac death, myocardial infarction, target vessel revascularization (TVR) or stent thrombosis. Effects of inverse variance random meta-analyses were described with relative risks (RR) and their 95% confidence intervals (CI). We also stratified analyses by type (triple [TAT] vs dual [DAT]) and duration (short-vs long-term) of antithrombotic therapy.

Results

Ten studies (3 RCTs; 7 cohorts) including 10,353 patients (DES: 59.6%) were identified. DES did not show higher risk of major bleeding than BMS (5.6% vs 6.9%, RR 1.07; 95%CI, 0.89–1.28, p = 0.47; I2 = 0%) or MACE (12% vs 13.6%; RR 0.96; 95%CI 0.81–1.13, p = 0.60; I2 = 44%). Although, DES almost decreased TVR risk (6.4% vs 8.4%, RR 0.78; 95%CI, 0.61–1.01, p = 0.06; I2 = 15%). Stratified analyses by type and duration of antithrombotic therapy showed no differences in major bleeding or MACE between both types of stents. In DES, long-term TAT showed higher major bleeding risk than long-term DAT (7.7% vs 4.7%, RR 1.48, 95%CI 1.08–2.03, p = 0.01; I2 = 12%). For both types of stents, MACE risk was similar between TAT and DAT.

Conclusions

In patients with AF undergoing PCI, DES had similar rate of major bleeding and MACE than BMS. DAT seems to be a safer antithrombotic therapy compared with TAT.

Introduction

Current generations of drug-eluting stents (DES) reduce the risk of in-stent restenosis and stent thrombosis compared with bare-metal stents (BMS) [1], but longer duration of dual antiplatelet therapy (DAPT) was believed to be required [2]. Patients undergoing percutaneous coronary intervention (PCI), with atrial fibrillation (AF) are at high risk for bleeding [3], and are usually excluded from trials evaluating stents or adjunctive therapies. Although current US guidelines recommend avoiding DES in patients at high bleeding risk on the basis of BMS having lower bleeding rates, the updated European guidelines indicate that second generation DES should be the default choice, coupled with shorter DAPT duration [4,5]. Moreover, the last European guidelines on myocardial revascularization recommend using DES in any PCI. Of interest, these recommendations include patients with high bleeding risk and clinical indication for oral anticoagulation [6]. If current DES are actually safer than BMS, patients fulfilling these untoward characteristics – a classical niche for BMS – would actually benefit from new-generation DES implantation. However, there are limited data in patients with AF, with a high number of comorbidities [7,8].

Triple antithrombotic therapy (TAT) has been the cornerstone of treatment in patients with AF undergoing PCI irrespective of the type of stent used but its safety has been questioned [4,5,9]. Five randomized controlled trials (RCTs) demonstrated reductions in bleeding events by shortening TAT duration or by skipping aspirin, using dual antithrombotic therapy (DAT) with clopidogrel plus vitamin K antagonists (VKA) or direct oral anticoagulants agents (DOAC) [[10], [11], [12], [13], [14]] More recently, a systematic review found that, compared with TAT, DAT shows a 47% relative lower risk of TIMI major or minor bleeding without differences in major adverse cardiovascular events (MACE) rates. However, the interaction between type of stent and DAT vs TAT has not been evaluated yet [15].

Therefore, we performed a systematic review to evaluate the safety and efficacy of DES vs BMS in patients with AF, in both RCTs and cohorts. We stratified our analyses by type and duration of antithrombotic therapy.

Section snippets

Methods

This systematic review was reported in accordance to the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analysis) guidelines [16].

We searched PubMed, EMBASE, Scopus, The Web of Science, the Cochrane Library and www.clinicaltrials.gov until May 31, 2019 for cohorts and RCTs in AF patients undergoing PCI with stent placement for acute coronary syndromes (ACS) or stable coronary artery disease. Our searches included all languages. The PubMed search strategy is available in the

Results

Our search identified 1551 publications. After removing duplicates, 1025 articles were screened by title and abstract. Overall, 96 articles were selected for full-text review based (Fig. 1). Three RCTs [[11], [12], [13]] and 7 cohort studies [[21], [22], [23], [24], [25], [26], [27]] involving 10,624 patients were included in our study. Of these, 9353 patients had primary outcome and secondary outcome data of interest (DES: n = 6180; 66.1%). Reasons for exclusion of 86 articles are listed in

Discussion

Our meta-analysis showed that DES did not show higher major bleeding risk than BMS in patients with AF undergoing PCI overall or after stratification by type of antithrombotic strategy and duration of treatment. This meta-analysis could not find differences in risk of MACE between both types of stents; however, in patients who received DES, a trend of a lower risk of TVR and a similar risk of stent thrombosis were observed in comparison to those who received BMS. Regarding antithrombotic

Conclusions

Our meta-analysis showed that BMS was not safer than DES decreasing bleeding events in patients with AF undergoing PCI either overall or after stratifying by type of antithrombotic strategy and duration of treatment. Regarding major bleeding, long-term DAT was found to be safer than TAT regardless of stent type. New scales and tools open new venues to escape from “one size fits all” strategies such as DAT, shifting to a new paradigm of “personalized medicine” able to select the optimal

Funding

This study was not supported by specific funding.

Declaration of competing interest

Dr. Sambola reports personal fees from: Boehringer-Ingelheim, Bristol-Myers and Pfizer, outside the submitted work.

Dr. Rello has nothing to disclose.

Dr. Soriano has nothing to disclose.

Dr. Bhatt discloses the following relationships - Advisory Board: Cardax, Elsevier Practice Update Cardiology, Medscape Cardiology, Regado Biosciences; Board of Directors: Boston VA Research Institute, Society of Cardiovascular Patient Care, TobeSoft; Chair: American Heart Association Quality Oversight Committee;

References (34)

  • K.H. Bønaa et al.

    Drug-eluting or bare-metal stents for coronary artery disease

    N. Engl. J. Med.

    (2016)
  • D.J. Kereiakes et al.

    Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial

    JAMA

    (2015)
  • S. Kralev et al.

    Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography

    PLoS One

    (2011)
  • C.T. January et al.

    2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society

    J. Am. Coll. Cardiol.

    (2014)
  • M. Valgimigli et al.

    2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)

    Eur. Heart J.

    (2018)
  • F.J. Neumann et al.

    ‘Ten commandments’ for the 2018 ESC/EACTS guidelines on myocardial revascularization

    Eur. Heart J.

    (2018)
  • P. Urban et al.

    Polymer-free drug-coated coronary stents in patients at high bleeding risk

    N. Engl. J. Med.

    (2015)
  • Cited by (4)

    • Advances in the development of biodegradable coronary stents: A translational perspective

      2022, Materials Today Bio
      Citation Excerpt :

      The implantation of a drug-eluting stent (DES) dramatically reduces the ISR rate. However, the delayed vascular re-endothelialization caused by the non-selective nature of drugs in the stents results in increased incidences of late stent thrombosis (LST) and very late stent thrombosis (VLST) [6–9]. Moreover, prolonged dual anti-platelet therapy (DAPT) after the implantation of a DES increases the risk of bleeding [7].

    • AUDITS: Mnemonical Approach for Atrial Fibrillation With Coronary Artery Disease

      2021, Journal for Nurse Practitioners
      Citation Excerpt :

      European guidelines indicate that new-generation DESs should be the default choice coupled with shorter dual-antiplatelet therapy (DAPT) duration.24 Equivocal results were seen in DESs compared with BMSs in the context of major bleeding risk in patients with AF undergoing PCI.24 European guidelines indicate the use of second-generation DESs for any PCI irrespective of clinical presentation, lesion type, or duration of antithrombotic therapy.24

    • Preparation and Properties of Biodegradable Zn - 3Cu - xMn Alloys

      2023, Dongbei Daxue Xuebao/Journal of Northeastern University
    1

    Senior authors.

    View full text